FourThought Financial Partners LLC Acquires Shares of 12,406 Corcept Therapeutics Incorporated (NASDAQ:CORT)

FourThought Financial Partners LLC acquired a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 12,406 shares of the biotechnology company’s stock, valued at approximately $625,000.

A number of other institutional investors have also made changes to their positions in the business. M&G PLC acquired a new position in shares of Corcept Therapeutics during the 3rd quarter worth about $11,173,000. Synergy Asset Management LLC grew its position in shares of Corcept Therapeutics by 131.3% during the 4th quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock worth $22,369,000 after buying an additional 262,503 shares during the period. Van ECK Associates Corp acquired a new position in shares of Corcept Therapeutics in the 4th quarter valued at approximately $4,483,000. Empowered Funds LLC acquired a new position in shares of Corcept Therapeutics in the 3rd quarter valued at approximately $1,784,000. Finally, Victory Capital Management Inc. grew its position in shares of Corcept Therapeutics by 49.2% in the 3rd quarter. Victory Capital Management Inc. now owns 41,823 shares of the biotechnology company’s stock valued at $1,936,000 after purchasing an additional 13,787 shares during the period. 93.61% of the stock is owned by institutional investors.

Insider Activity

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $59.46, for a total transaction of $130,812.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Sean Maduck sold 20,000 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total value of $1,007,800.00. Following the sale, the insider now directly owns 85,318 shares of the company’s stock, valued at $4,299,174.02. This represents a 18.99 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 26,600 shares of company stock valued at $1,399,576. 20.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on CORT shares. StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Canaccord Genuity Group upped their price target on Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Corcept Therapeutics in a research report on Friday, February 7th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $88.25.

Corcept Therapeutics Trading Down 0.9 %

NASDAQ CORT opened at $61.23 on Wednesday. The company has a market cap of $6.42 billion, a PE ratio of 48.60 and a beta of 0.58. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. Corcept Therapeutics Incorporated has a 12 month low of $20.84 and a 12 month high of $75.00. The stock has a 50 day moving average of $59.38 and a 200-day moving average of $51.07.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.